New combo aims to mop up hidden cancer cells after myeloma transplant
NCT ID NCT05690984
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether a combination of isatuximab, lenalidomide, and dexamethasone can eliminate minimal residual disease (MRD) in multiple myeloma patients who still have detectable cancer cells after a stem cell transplant. About 30 adults will receive the drug combo for up to 12 cycles. The main goal is to see how many become MRD-negative, meaning no cancer cells are found by a sensitive genetic test.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
isatuximab, lenalidomide, and dexamethasone
What this could lead to
If successful, this combination could help eliminate remaining cancer cells after transplant, potentially leading to longer remission for multiple myeloma patients.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to all patients. The drugs can cause side effects like infections, fatigue, and blood clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States